Abstract
To investigate the feasibility of developing a new tenoxicam plaster, the effects of vehicles and penetration enhancers on thein vitro permeation of tenoxicam from a pressure-sensitive adhesive (PSA) matrices across the dorsal hairless mouse skin were studied. Vehicles employed in this study were propylene glycol (PG)-oleyl alcohol (OAI), PG-oleic acid (OA), and diethylene glycol monoethyl ether (DGME)-propylene glycol monolaurate (PGML) cosolvents with/without fatty acids. In this study, amines such as triethanolamine (TEA) and tromethamine (TM) were additionally used as a solubilizer. Among PSAs used, Duro-TakΘ87–2510 showed much higher release rate than either Duro-TakΘ 87-2100 or Duro-TakΘ87–2196. The relatively high flux rate was obtained with the formulation of DGME-PGML (40:60, v/v) with 3% OA and 5% TM, and the flux increased as a function of the dose; the initial flux up to 12 h was 4.98 Θ 1.38 μg/cm2/h at the tenoxicam dose of 50 mg/70 cm2. This flux was much higher than that of a commercial piroxicam patch (TrastΘ) (1.24Θ0.73 μg/ cm2/hr) with almost only one-third that of the commercial patch. Therefore, these observations indicated that these composition of tenoxicam plaster may be practically applicable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albengres, E., Urien, S., Barre, J., Nguyen, P., Bree, F., Jolliet, P., Tillement J. P., Tsai, R.S., Carrupt, P. A., and Testa, B., Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity,Int. J. Tiss. Reac., 16, 125–134 (1993).
Aungst, B. J., Blake, J. A., and Hussain, M. A., Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines.Pharm. Res., 7, 712–718 (1990).
Barclay, C. A. and Traballi, C. A., Evaluation of tenoxicam in rheumatology-clinical trial results in Argentina and Brazil.Eur. J. Rheumatol. Infla., 9, 712–718 (1990).
Barry, B. W., 1983. Dermatological Formulations. Marcel Dekker, New York, pp. 1–48.
Barry, B. W., Mode of action of penetration enhancers in human skin.J. Controlled Rel., 6, 85–97 (1987).
Borodkin, S. and Tucker, F.E., Drug release from hydroxy-propyl cellulose-polyvinyl acetate films.J. Pharm. Sci., 63, 1359–1363 (1974).
Caughey, D. and Waterworth, R. F., A study of the safety of tenoxicam in general practice.New Zealand Med. J., 102, 582–583 (1989).
Chien, Y. W. and Lambert, H. J., Controlled drug release from polymeric delivery devices II: differentiation between partition-controlled and matrix-controlled drug release mechanism.J. Pharm. Sci., 63, 515–519 (1974).
Green, P. G., Guy, R. H., and Hadgraft, J., In vitro and in vivo enhancement of skin permeation with oleic and lauric acids.Int. J. Pharm., 48, 103–111 (1988).
Gwak, H. S. and Chun, I. K., Effect of vehicles and penetration enhancers on thein vitro percutaneous absorption of tenoxicam through hairless mouse skin.Int. J. Pharm., submitted (2001).
Hsu, L. R., Huang, Y. B., Wu, P. C., and Tsai, Y. H., Percutaneous absorption of piroxicam from FAPG base through rat skin: effects of oleic acid and saturated fatty acid added to FAPG base.Drug Dev. Ind. Pharm., 20, 1425–1437 (1994).
Kim, J. H., Cho, Y. J., and Choi, H. K., Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin.Int. J. Pharm., 196, 105–113 (2000).
Pellet, M. A., Davis, A. F., and Hadgraft, J., Effect of supersaturation on membrane transport: 2. piroxicam.Int. J. Pharm., 111, 1–6 (1994).
Roy, S. D., Gutierrez, M., Flynn, G. L., and Cleary, G. W., Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design,J. Pharm. Sci., 85, 491–495 (1996).
Santoyo, S., Arellano, A., Ygartua, P., and Martin, C., Penetration enhancer effects on the in vitro percutaneous absorption of piroxicam through rat skin.Int. J. Pharm., 117, 219–224 (1995).
Todd, P. A. and Clissold, S. P., An update of its pharmacology and therapeutic efficacy in rheumatic diseases.Drugs, 41, 625–646 (1991).
Valdes, E. F., Barclay, C. A., and Traballi, C. A., Tenoxcam, a novel long-acting anti-inflammatory and analgesic drug of the oxicam class: double-blind comparative study with piroxicam in patients with gona or coxarthrosis.Curr. Ther. Res., 37, 937–944 (1985).
Yamada, M., Uda, Y., and Tanigawara, Y., Mechanism of enhancement of percutaneous absorption of molsidomine by oleic acid.Chem. Pharm. Bull., 35, 3399–3406 (1987).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gwak, H.S., Chun, K. In Vitro Percutaneous absorption of tenoxicam from pressure-sensitive adhesive matrices across the hairless mouse skin. Arch Pharm Res 24, 578–583 (2001). https://doi.org/10.1007/BF02975169
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02975169